Abstract The Korean Society of Heart Failure (KSHF) guidelines aim to provide physicians
with evidence-based recommendations for the management of patients with heart failure …

Cardiac amyloidosis is caused by the extracellular deposition of amyloid fibrils in the heart,
involving not only the myocardium but also any cardiovascular structure. Indeed, this …

Rationale and Objectives Strain measured by feature tracking technique represents the
degree of deformation and reflects the systolic and diastolic function of the heart. Our …

Introduction Cardiac amyloidosis (CA) shares similar clinical and imaging characteristics
(eg, hypertrophic phenotype) with aortic stenosis (AS), but its prognosis is generally worse …

It is well recognized that amyloid protein can infiltrate many regions of the body. This can
include the peripheral nerves, the liver, kidney, spleen, the gastrointestinal tract, and most …

Cardiac amyloidosis (CA), a significant condition resulting in infiltrative cardiomyopathy and
heart failure with preserved ejection fraction (HFpEF), is caused by extracellular deposition …

Amyloidosis is a protein deposition disorder in which insoluble fibril structures accumulate in
the bodily tissues damaging the organ function. Cardiac amyloidosis is a severe but under …

Nanoparticles hold a great potential for therapeutic targeting due to their ability to improve
the stability of encapsulated cargo and promote the transport of cargo across membranes to …

Cardiac amyloidosis, increasingly recognized for its significant impact on global heart health
and patient survival, demands a thorough review to understand its complexity and the …

Cardiac amyloidosis (CA) represents an emerging challenge in cardiovascular medicine,
with notable clinical overlaps and diagnostic complexities when coexisting with coronary …